You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 6,955,717

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,955,717

Title:	Crystals and structure of Synagis Fab
Abstract:	The present invention provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab, and subsets thereof, and methods of using them.
Inventor(s):	Johnson; Leslie S. (Darnestown, MD), Braden; Bradford (Baltimore, MD)
Assignee:	Medimmune Inc. (Gaithersburg, MD) Bowie State University (Bowie, MD)
Application Number:	10/135,636
Patent Claims:	1. A method of identifying a Synagis binding compound, comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally screen a candidate compound for an ability to bind the Synagis antigen binding site. 2. The method of claim 1 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity. 3. A method of identifying a Synagis binding compound, comprising the steps of (a) using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally screen a candidate compound for an ability to bind the Synagis antigen binding site, (b) synthesizing the candidate compound; and (c) screening the candidate compound for Synagis binding activity, wherein the structural information comprises the atomic structure coordinates of residues comprising a Synagis CDR. 4. The method of claim 3 in which the Synagis CDR is L1, L2, L3, H1, H2 or H3. 5. The method of claim 4 in which the structural information comprises the antigen binding site of Synagis. 6. The method of claim 5 in which the structural information comprises the Fv fragment of Synagis. 7. The method of claim 6 in which the structural information comprises the Fab fragment of Synagis. 8. A method of identifying a Synagis binding compound comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally design a synthesizable candidate compound that binds Synagis. 9. The method of claim 8 in which the computational design comprises the steps of: identifying chemical entities or fragments capable of associating with the Synagis binding site; and assembling the chemical entities or fragments into a single molecule to provide the structure of the candidate compound. 10. The method of claim 9 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity. 11. A method of identifying a Synagis binding compound comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally design a synthesizable candidate compound that binds Synagis, wherein the structural information comprises the atomic structure coordinates of residues comprising a Synagis CDR. 12. The method of claim 11 in which the Synagis CDR is L1, L2, L3, H1, H2 or H3. 13. The method of claim 11 in which the structural information comprises the antigen binding site of Synagis. 14. The method of claim 11 in which the structural information comprises the Fv fragment of Synagis. 15. The method of claim 12 in which the structural information comprises the Fab fragment of Synagis. 16. The method of claim 11 in which the computational design comprises the steps of: identifying chemical entities or fragments capable of associating with the Synagis binding site; and assembling the chemical entities or fragments into a single molecule to provide the structure of the candidate compound. 17. The method of claim 16 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.

Details for Patent 6,955,717

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998	⤷ Try a Trial	2021-05-01
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004	⤷ Try a Trial	2021-05-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.